Top

International Journal of Mental Health and Addiction

Open Access 26-09-2023 | Opioids | Original Article

Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness

Authors: Joshua C. Black, Nicole Schow, Hannah L. Burkett, Morgan Pena, Jennifer S. Jewell, Annika Czizik, Andrew A. Monte, Richard C. Dart

Published in: International Journal of Mental Health and Addiction

Abstract

Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses (anxiety disorder, major depressive disorder [MDD], post-traumatic stress disorder [PTSD], and bipolar disorder) and serotonergic psychedelic or MDMA use were combined. Any psychedelic use among adults with psychiatric illness history (anxiety: 5.1% [95% CI: 4.7, 5.6]; MDD: 5.1% [4.3, 5.8]; PTSD: 6.9% [5.9, 7.9]; bipolar: 9.2% [8.0, 10.5]) was more prevalent than the general population (2.6% [2.5, 2.8]). Significant increases in scores were associated with psychedelic use independent of other concurrent drug use, but increases were smaller than for opioids or stimulants. Approaches to managing SUD risks with psychedelics should differ from past approaches for other drugs.

Available only for authorised users

Andersen, K. A. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatrica Scandinavica, 143(2), 101–118. https://doi.org/10.1111/acps.13249CrossRefPubMed

Barnett, B. S. (2022). Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health. Journal of Psychopharmacology, 36(10), 1097–1099. https://doi.org/10.1177/02698811221123051CrossRefPubMed

Belouin, S. J., Averill, L. A., Henningfield, J. E., Xenakis, S. N., Donato, I., Grob, C. S., Berger, A., Magar, V., Danforth, A. L., & Anderson, B. T. (2022). Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology, 219, 109214. https://doi.org/10.1016/j.neuropharm.2022.109214CrossRefPubMed

Bender, D., & Hellerstein, D. J. (2022). Assessing the risk-benefit profile of classical psychedelics: A clinical review of second-wave psychedelic research. Psychopharmacology, 239(6), 1907–1932. https://doi.org/10.1007/s00213-021-06049-6CrossRefPubMed

Black, J. C., Forber, A., Severtson, S. G., Rockhill, K., May, K. P., Amioka, E., Schwarz, J., Iwanicki, J., & Dart, R. C. (2021). Drug product dispensing and estimates of use in a general population survey as a signal detection problem. Pharmacoepidemiology and Drug Safety, 30(8), 1132–1139. https://doi.org/10.1002/pds.5260CrossRefPubMed

Black, J. C., Rockhill, K., Forber, A., Amioka, E., May, K. P., Haynes, C. M., Dasgupta, N., & Dart, R. C. (2019). An online survey for pharmacoepidemiological investigation (survey of non-medical use of prescription drugs program): Validation study. Journal of Medical Internet Research, 21(10), e15830.CrossRefPubMedCentralPubMed

Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022). Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Journal of Psychopharmacology (Oxford, England), 36(10), 1100–1117. https://doi.org/10.1177/02698811221116926CrossRefPubMed

Buckley, P. F. (2006). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. The Journal of Clinical Psychiatry, 67(Suppl 7), 5–9. https://www.ncbi.nlm.nih.gov/pubmed/16961418PubMed

Calderon, S. N., Hunt, J., & Klein, M. (2018). A regulatory perspective on the evaluation of hallucinogen drugs for human use. Neuropharmacology, 142, 135–142. https://doi.org/10.1016/j.neuropharm.2017.11.028CrossRefPubMed

Deville, J., Sarndal, C., & Sautory, O. (1993). Generalized raking procedures in survey sampling. Journal of the American Statistical Association, 88(423), 1013–1020.CrossRef

Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. The New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443CrossRefPubMed

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513CrossRefPubMed

Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151–158. https://doi.org/10.1177/02698811211073759CrossRefPubMed

Henningfield, J. E., Ashworth, J., Heal, D. J., & Smith, S. L. (2023). Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. Journal of psychopharmacology (Oxford, England), 37(1), 33–44. https://doi.org/10.1177/02698811221140004CrossRefPubMed

Henningfield, J. E., Coe, M. A., Griffiths, R. R., Belouin, S. J., Berger, A., Coker, A. R., Comer, S. D., Heal, D. J., Hendricks, P. S., Nichols, C. D., Sapienza, F., Vocci, F. J., & Zia, F. Z. (2022). Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology, 218, 109220. https://doi.org/10.1016/j.neuropharm.2022.109220CrossRefPubMed

Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143–166. https://doi.org/10.1016/j.neuropharm.2018.05.012CrossRefPubMedCentralPubMed

Jones, G., Ricard, J. A., Lipson, J., & Nock, M. K. (2022). Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Scientific Reports, 12(1), 4099. https://doi.org/10.1038/s41598-022-08085-4CrossRefPubMedCentralPubMed

Kroll, D. S., Feldman, D. E., Wang, S. A., Zhang, R., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G. J. (2020). The associations of comorbid substance use disorders and psychiatric conditions with adolescent brain structure and function: A review. Journal of the Neurological Sciences, 418, 117099. https://doi.org/10.1016/j.jns.2020.117099CrossRefPubMedCentralPubMed

Leonard, J. B., Anderson, B., & Klein-Schwartz, W. (2018). Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. Journal of Psychopharmacology, 32(12), 1286–1294. https://doi.org/10.1177/0269881118793086CrossRefPubMed

Lowe, H., Toyang, N., Steele, B., Grant, J., Ali, A., Gordon, L., & Ngwa, W. (2022). Psychedelics: Alternative and potential therapeutic options for treating mood and anxiety disorders. Molecules, 27(8). https://doi.org/10.3390/molecules27082520

Malcolm, B., & Thomas, K. (2022). Serotonin toxicity of serotonergic psychedelics. Psychopharmacology, 239(6), 1881–1891. https://doi.org/10.1007/s00213-021-05876-xCrossRefPubMed

Meade, A. W., & Craig, S. B. (2012). Identifying careless responses in survey data. Psychological Methods, 17(3), 437–455. https://doi.org/10.1037/a0028085CrossRefPubMed

Mercer, A. W., Kreuter, F., Keeter, S., & Stuart, E. A. (2017). Theory and Practice in Nonprobability Surveys. Public Opinion Quarterly, 81(S1), 250–271. https://doi.org/10.1093/poq/nfw060CrossRef

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora, G. M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3CrossRefPubMedCentralPubMed

Morton, E., Sakai, K., Ashtari, A., Pleet, M., Michalak, E. E., & Woolley, J. (2023). Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. Journal of Psychopharmacology, 37(1), 49–60. https://doi.org/10.1177/02698811221131997CrossRefPubMed

Munafo, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., & Cantarella, G. (2022). Psilocybin for depression: From credibility to feasibility, what’s missing? Pharmaceuticals (Basel), 16(1). https://doi.org/10.3390/ph16010068

Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478CrossRefPubMedCentralPubMed

Ong, A., & Weiss, D. (2000). The impact of anonymity on responses to sensitive questions. Journal of Applied Social Psychology, 30(8), 1691–1708.CrossRef

Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osorio, F. L., Sanches, R., Dos Santos, R. G., Tofoli, L. F., de Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvao-Coelho, N. L., Lobao-Soares, B., et al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine, 49(4), 655–663. https://doi.org/10.1017/S0033291718001356CrossRefPubMedCentralPubMed

Psilocybin Therapy for Depression in Bipolar II Disorder (BAP). (2023). National Library of Medicine. Retrieved 3 March 2023 from https://clinicaltrials.gov/ct2/show/NCT05065294

Rose, G. (2001). Sick individuals and sick populations. International Journal of Epidemiology, 30(3), 427–434. https://doi.org/10.1093/ije/30.3.427CrossRefPubMed

Rosenbaum, D., Weissman, C., Anderson, T., Petranker, R., Dinh-Williams, L. A., Hui, K., & Hapke, E. (2020). Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. Journal of psychopharmacology (Oxford, England), 34(6), 612–622. https://doi.org/10.1177/0269881120908004CrossRefPubMed

Rucker, J., Jafari, H., Mantingh, T., Bird, C., Modlin, N. L., Knight, G., Reinholdt, F., Day, C., Carter, B., & Young, A. (2021). Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. BMJ Open, 11(12), e056091. https://doi.org/10.1136/bmjopen-2021-056091CrossRefPubMedCentralPubMed

Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Long, D. M., & Hendricks, P. S. (2022). Prevalence and associations of classic psychedelic-related seizures in a population-based sample. Drug and Alcohol Dependence, 239, 109586. https://doi.org/10.1016/j.drugalcdep.2022.109586CrossRefPubMedCentralPubMed

Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2023). Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. Journal of Affective Disorders, 326, 105–110. https://doi.org/10.1016/j.jad.2023.01.073CrossRefPubMed

Stewart, R. E., Cardamone, N. C., Schachter, A., Becker, C., McKay, J. R., & Becker-Haimes, E. M. (2023). A systematic review of brief, freely accessible, and valid self-report measures for substance use disorders and treatment. Drug and Alcohol Dependence, 243, 109729. https://doi.org/10.1016/j.drugalcdep.2022.109729CrossRefPubMed

Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved March 3, 2023, from https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Babler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport, 9(17), 3897–3902. https://doi.org/10.1097/00001756-199812010-00024CrossRefPubMed

Von Gunten, C. D., & Wu, L. T. (2021). Comorbid substance use disorder profiles and receipt of substance use disorder treatment services: A national study. Journal of Studies on Alcohol and Drugs, 82(2), 246–256. https://doi.org/10.15288/jsad.2021.82.246CrossRef

Winstock, A. R., Timmerman, C., Davies, E., Maier, L. J., Zuhparris, A., Ferris, J. A., Barratt, M. J., & Kuypers, K. P. C. (2021). 2020 Psychedelics Key Findings Report. Global Drug Survey (GDS).

Yudko, E., Lozhkina, O., & Fouts, A. (2007). A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. Journal of Substance Abuse Treatment, 32, 189–198.CrossRefPubMed

Title: Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness
Authors: Joshua C. Black
Nicole Schow
Hannah L. Burkett
Morgan Pena
Jennifer S. Jewell
Annika Czizik
Andrew A. Monte
Richard C. Dart
Publication date: 26-09-2023
Publisher: Springer US
Keywords: Opioids
Opioids
Post Traumatic Stress Disorder
Published in: International Journal of Mental Health and Addiction
Print ISSN: 1557-1874
Electronic ISSN: 1557-1882
DOI: https://doi.org/10.1007/s11469-023-01163-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content